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Increased susceptibility to 
cortical spreading depression and 
epileptiform activity in a mouse 
model for FHM2
Lieke Kros1,4, Karin Lykke-Hartmann2,3 & Kamran Khodakhah  1
Migraine is a highly prevalent, debilitating, episodic headache disorder affecting roughly 15% of 
the population. Familial hemiplegic migraine type 2 (FHM2) is a rare subtype of migraine caused 
by mutations in the ATP1A2 gene, encoding the α2 isoform of the Na+/K+-ATPase, predominantly 
expressed in astrocytes. Differential comorbidities such as epilepsy and psychiatric disorders manifest 
in patients. Using a mouse model harboring the G301R disease-mutation in the α2 isoform, we set to 
unravel whether α2+/G301R mice show an increased susceptibility for epilepsy and cortical spreading 
depression (CSD). We performed in vivo experiments involving cortical application of KCl in awake head-
restrained male and female mice of different age groups (adult and aged). Interestingly, α2+/G301R mice 
indeed showed an increased susceptibility to both CSD and epileptiform activity, closely replicating 
symptoms in FHM2 patients harboring the G301R and other FHM2-causing mutations. Additionally, this 
epileptiform activity was superimposed on CSDs. The age-related alteration towards CSD indicates the 
influence of female sex hormones on migraine pathophysiology. Therefore, the FHM2, α2+/G301R mouse 
model can be utilized to broaden our understanding of generalized epilepsy and comorbidity hereof in 
migraine, and may be utilized toward future selection of possible treatment options for migraine.
Migraine is a highly prevalent, debilitating, episodic headache disorder affecting roughly 15% of the population1. 
A migraine attack is characterized by a severe, long lasting headache that often coincides with nausea and neuro-
logical signs and can be preceded by transient neurological symptoms; an aura2. Prevalence of migraine is higher 
in women than men and severity and frequency of headache episodes often decrease after menopause in women 
or with age in general1,3.
A rare subtype of this disorder is familial hemiplegic migraine type 2 (FHM2), an autosomal dominant form 
of migraine characterized by the occurrence of an aura with hemiparesis (one-sided motor weakness) that shows 
a high degree of comorbidity with epilepsy2,4. In most cases, FHM2 is caused by a loss of function mutation in the 
ATP1A2 gene encoding the α2-isoform of the Na+/K+-ATPase, predominantly found in astrocytes4–6. The Na+/
K+-ATPase is a pump that actively transports potassium into, and sodium out of, a cell to maintain stable trans-
membrane ionic gradients7. FHM2 related mutations in the ATP1A2 gene cause haploinsufficiency and result in 
diminished astrocyte function, rendering them insufficiently capable of clearing excess K+ from the extracellular 
space, and excess glutamate from the synaptic cleft8,9.
Two Italian families with several members suffering from FHM2 caused by the G301R mutation have been 
described10,11. This specific mutation causes a particularly severe phenotype with comorbidity of migraine with 
epilepsy, coma, motor symptoms and psychiatric disorders like depression and obsessive compulsive disorder 
(OCD)10,11. Based on this mutation, a new mouse model for FHM2 was generated and characterized12. Initial 
phenotypical investigation showed hypo-locomotion, OCD-like behavior and stress-induced depression. The 
phenotypes were generally more severe in females and could be rescued by blocking female sex hormones12.
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The neurobiological process underlying the migraine aura is thought to be cortical spreading depression 
(CSD); a wave of initial neuronal and glial depolarization followed by prolonged depression that slowly propa-
gates over the cerebral cortex13–15. Although the phenomenon has been described as early as 194414, mechanisms 
underlying spontaneous initiation and propagation of CSDs, and the relative contribution of glia and neurons, 
remain incompletely understood16,17. Several more recent studies have implicated CSD in causing the subsequent 
headache through activation of the trigeminal system13,18–22. Susceptibility to CSD, defined as a combination 
of CSD frequency and propagating speed, has been used to determine the validity of previously created FHM1 
mouse models23. One mouse model harboring the human FHM2-related W887R mutation has been generated24 
and α2+/W887R mice showed a reduced induction threshold for CSD using electrical stimulation in anesthe-
tized animals25. Despite several studies, a deep understanding of the neurophysiology associated with CSD and 
migraine remains to be achieved in experiments in an awake setting to be able to verify and confirm observations 
from in vitro studies and anesthetized settings as well as to allow for assessment of epilepsy susceptibility.
Here, we set to unravel whether a mouse model of FHM2 harboring the G301R mutation (α2+/G301R mice) 
shows an increased susceptibility to CSD and/or a decreased threshold for epileptiform activity. To address this, 
we performed experiments involving occipital application of KCl in awake, head-restrained heterozygous α2+/
G301R mice and wild type littermates to determine differences in CSD susceptibility. Interestingly, in addition to 
generating CSDs, these experiments consistently resulted in epileptiform activity in α2+/G301R mice. About half of 
the α2+/G301R mice showed continuous epileptiform activity that was superimposed on CSDs.
Results
α2+/G301R mice showed an increased susceptibility to CSD. We first investigated the susceptibility of 
α2+/G301R mice to cortical spreading depression defined by CSD frequency and propagating speed upon occipital 
application of 300 mM KCl (as described in23). Electrocorticographical (ECoG) recordings were made bilater-
ally from M1 and unilaterally from S1 (left side) while a small craniotomy over the left occipital lobe allowed 
for application of KCl (Fig. 1A,B). After several days of post-surgical recovery, experiments were performed in 
awake, head-restrained heterozygous α2+/G301R mice (N = 9 per group) and their wild type littermates (N = 8 for 
males and females and N = 7 for aged males and post-menopausal females). Since migraine is more prevalent in 
women than men1, and often improves after menopause3 or with age in general26, we compared both genders in 
two different age groups (2–8 months and 14–20 months).
The occurrence of CSDs upon application of KCl could be observed in the ipsilateral hemisphere of all mice 
whereas the phenomenon was absent on the contralateral side (Fig. 1C). We found that all groups of α2+/G301R mice 
showed an increased CSD frequency as compared to their wild type littermates (p < 0.05 for all; Mann Whitney 
U tests; Fig. 1C,D; Table 1). Whereas no differences were found between wild type groups (H(3) = 2.08, p = 0.556; 
Kruskal-Wallis test), we did find significant differences between the groups of α2+/G301R mice (H(3) = 19.91, 
p < 0.001; Kruskal-Wallis test). More specifically, the post-menopausal females showed a significantly reduced 
CSD frequency as compared to males (t(16) = 13.22, p < 0.05), females (t(16) = 21.72, p < 0.001) and aged males 
(t(16) = 13.28, p < 0.05) (Dunn’s Multiple Comparison tests with Bonferroni correction; Fig. 1C,D; Table 1).
For propagating speed, calculated by dividing the distance between the two electrodes on the left hemisphere 
(2 mm) by the time difference in CSD onset, we found a similar pattern of differences between α2+/G301R mice and 
their wild type littermates. All groups of α2+/G301R mice showed an increased CSD propagating speed compared to 
their wild type counterparts (p < 0.05 for all; Mann Whitney U tests; Fig. 1E,F; Table 1). However, whereas there 
were clear differences between α2+/G301R post-menopausal females and the other α2+/G301R groups in CSD fre-
quency, such an effect could not be found for propagating speed between α2+/G301R groups (H(3) = 5.48, p = 0.140; 
Kruskal-Wallis test) or wild type groups (H(3) = 0.63, p = 0.890; Kruskal-Wallis test; Fig. 1E,F, Table 1). Together, 
these data indicate that α2+/G301R mice, indeed show a significantly increased susceptibility to cortical spreading 
depression and remarkably, this susceptibility decreases after menopause in females but not with age in males, 
suggesting that female hormones influence migraine pathophysiology.
Increased susceptibility to generalized epileptiform activity in α2+/G301R mice. All α2+/G301R 
mice and some wild type littermates showed various degrees of epileptiform activity during CSD experiments 
(Fig. 2A). This epileptiform activity could range from a few bouts of spikes to a full tonic-clonic seizure- like 
episode with the accompanying electrophysiological and behavioral correlates (tonic-clonic movements, foam 
around the mouth and unresponsiveness).
Whereas the majority of wild type littermates did not show any epileptic spikes and the ones that did merely 
showed some bouts late in the recording, all α2+/G301R mice showed epileptiform activity (Fig. 2B). Aged males and 
post-menopausal females showed a lower percentage of animals that developed continuous epileptiform activity 
than did younger mice in both the α2+/G301R and wild type populations (Fig. 2B). This indicates that susceptibility 
to epileptiform activity may decrease with age. The onset of the epileptiform activity, defined by the time point 
at which the first occurrence of epileptic spikes was observed, differed between the groups of α2+/G301R mice and 
wild types (H(4) = 20.16, p < 0.001; Kruskal-Wallis test; Fig. 2C,D, Table 2) (wild type data was pooled for this 
analysis due to the low number of wild types developing any epileptiform activity). Post hoc analyses revealed 
that the onset was earlier in α2+/G301R males (t(17) = −19.94, p < 0.05), females (t(17) = −24.61, p ≤ 0.001) and 
aged males (t(17) = −20.17, p < 0.05) as compared to wild types, whereas the α2+/G301R post-menopausal females 
did not differ from either the other α2+/G301R groups or the wild types indicating that susceptibility to epilepti-
form activity too may decrease after menopause (Dunn’s Multiple Comparison tests with Bonferroni correction; 
Fig. 2C; Table 2).
The epileptiform activity always started out as a few spikes just after the depression and would progressively 
develop into broader bouts, which would become continuous in some animals (Fig. 2D). In four cases, the 
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tonic-clonic episode was lethal and mice died shortly after the experiment despite our efforts to rescue each 
mouse by anesthetizing them after the experiment to abort the epileptiform activity.
Because both epileptiform activity and CSD can be caused by a high extracellular potassium concentra-
tion13,27,28 and the efficiency of astrocytes in α2+/G301R mice to clear the extracellular space is affected, we next 
wanted to see whether onset and severity of epileptiform activity could be related to the CSD frequency. Severity 
of epileptiform activity was defined as the average power at dominant frequency (0.5–4 Hz; Fig. 3A) in the last 
10 minutes of the recording normalized to the average power in this frequency range in the first 10 minutes. 
Combining all data from α2+/G301R mice, we a found that a moderate yet significant portion of the variance in 
both severity of epileptiform activity (t(35) = 3.18, p ≤ 0.001; linear regression; Fig. 3B, Table 3) and onset of 
Figure 1. Increased susceptibility to cortical spreading depression in α2+/G301R mice. (A) Schematic 
representation of the placement of ECoG electrodes and the craniotomy allowing for the application of KCl. (B) 
Picture of a mouse with implanted electrodes, corresponding connector and small 3D printed cylinders to allow 
head-restraining secured to its skull. The green area is non-toxic silicone to secure and protect the craniotomy. 
(C) Representative examples of 15 min ECoG traces of M1 left (pink), S1 left (black) and M1 right (green, 
contralateral) during occipital application of KCl in wild type mice (top), α2+/G301R mice (middle) and α2+/G301R 
post-menopausal (PM) females (bottom). (D) Quantification of CSD frequency based on 1 hour recordings 
in all groups of animals; male (light blue), female (pink), post-menopausal (PM) female (purple) and aged 
male (dark blue) α2+/G301R mice and their wild type littermates (N = 7–9). Each black dot represents an animal, 
error bars represent standard deviations. *p < 0.05, ***p < 0.001 (Mann Whitney U tests and Kruskal-Wallis 
test followed by Dunn’s Multiple Comparison tests with Bonferroni correction; see Table 1) (E) Representative 
example of a single CSD in a wild type (left) and α2+/G301R mouse (right) in the time difference in CSD onset 
between S1 (black) and M1 (pink) is depicted with dotted lines and arrows. (F) Quantification of propagating 
speed for all groups as in (D). Error bars represent standard deviations, ***p < 0.001 (Mann Whitney U tests 
and Kruskal-Wallis test and subsequent Dunn’s Multiple Comparison tests with Bonferroni correction; see 
Table 1).
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epileptiform activity (t(35) = −5.24, p < 0.001; linear regression; Fig. 3C, Table 3) could be explained by the vari-
ance in CSD frequency; suggesting that a more severe epileptiform phenotype correlates to a more severe degree 
of CSD susceptibility. A similarly moderate but significant relation was found between onset and severity of epi-
leptiform activity (t(35) = −3.84, p ≤ 0.001; linear regression; Fig. 3D, Table 3). These analyses suggest that higher 
susceptibility to CSD and a more severe degree of epileptiform activity indeed often coincide in α2+/G301R mice, 
likely related to increases in extracellular potassium concentration.
Further investigation of the spatial and temporal relations between CSD and epileptiform activity, yielded 
interesting observations. First, whereas a CSD does not spread to the other hemisphere, the epileptiform activity 
is generalized (Fig. 4A,B). Furthermore, whereas epileptiform activity was confined to the upstroke after the 
trough in a CSD and the subsequent after-depolarization in early stages of an experiment (Fig. 4A left panel), it 
became fully superimposed on CSDs in later stages (Fig. 4A right panel) in mice that developed severe epilepti-
form activity. Although the waveform and power spectra change over the course of a CSD (Fig. 4B,C), epileptic 
spikes continue during the depression. In order to assess the similarity and timing differences of this epileptiform 
activity between the different cortical areas, we performed cross-correlations on data obtained from α2+/G301R 
mice. Investigating raw data on a magnified time scale revealed differences in shape and timing between the chan-
nels (Fig. 4D) which was reflected in the average cross correlations of the three possible channel combinations 
(Fig. 4E). Pairwise analyses revealed that the correlation between S1 on the left hemisphere and M1 on the right 
was significantly lower than the cross correlation between M1 and S1 on the same hemisphere or ipsilateral and 
contralateral M1 (t(32) = 4.30, p ≤ 0.001 and t(32) = 3.74, p ≤ 0.001 respectively; paired t-tests; Fig. 4F, Table 4). 
Compared groups N p-value H, t or U-value Statistical test
Differences in CSD susceptibility
Wild types 30 0.556 H(3) = 2.08 Independent samples
(Males, females, aged males and PM females) (8, 8, 7, 7) Kruskal-Wallis test
α2+/G301R mice 36 <0.001 H(3) = 19.91 Independent samples
(Males, females, aged males and PM females) (9, 9, 9, 9) Kruskal-Wallis test
α2+/G301R males 9 0.507 t(16) = −8.50 Dunn’s Multiple Comparison Test
α2+/G301R females 9 (Bonferroni correction)
α2+/G301R males 9 1.000 t(16) = −0.06 Dunn’s Multiple Comparison Test
α2+/G301R aged males 9 (Bonferroni correction)
α2+/G301R males 9 <0.05 t(16) = 13.22 Dunn’s Multiple Comparison Test
α2+/G301R PM females 9 (Bonferroni correction)
α2+/G301R females 9 0.519 t(16) = 8.44 Dunn’s Multiple Comparison Test
α2+/G301R aged males 9 (Bonferroni correction)
α2+/G301R females 9 <0.001 t(16) = 21.72 Dunn’s Multiple Comparison Test
α2+/G301R PM females 9 (Bonferroni correction)
α2+/G301R aged males 9 <0.05 t(16) = 13.28 Dunn’s Multiple Comparison Test
α2+/G301R PM females 9 (Bonferroni correction)
Wild type males 8 <0.001 U(15) = 72.00 Mann-Whitney U test
α2+/G301R males 9
Wild type females 8 <0.001 U(15) = 72.00 Mann-Whitney U test
α2+/G301R females 9
Wild type aged males 7 <0.001 U(14) = 63.00 Mann-Whitney U test
α2+/G301R aged males 9
Wild type PM females 7 <0.001 U(14) = 63.00 Mann-Whitney U test
α2+/G301R PM females 9
Differences in Propagating speed
Wild types 27 0.890 H(3) = 0.63 Independent samples
(Males, females, aged males and PM females) (8, 6, 7, 6) Kruskal-Wallis test
α2+/G301R mice 36 0.140 H(3) = 5.48 Independent samples
(Males, females, aged males and PM females) (9, 9, 9, 9) Kruskal-Wallis test
Wild type males 8 <0.001 U(15) = 72.00 Mann-Whitney U test
α2+/G301R males 9
Wild type females 6 <0.001 U(13) = 52.50 Mann-Whitney U test
α2+/G301R females 9
Wild type males 7 ≤0.001 U(14) = 62.50 Mann-Whitney U test
α2+/G301R aged males 9
Wild type males 6 <0.001 U(13) = 54.00 Mann-Whitney U test
α2+/G301R PM females 9
Table 1. Details of statistical tests performed on data shown in Figure 1D and F.
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Figure 2. Increased susceptibility to epileptiform activity in α2+/G301R mice. (A) Representative examples of 
the last 15 min of 1 hour ECoG recordings (M1) showing various degrees of epileptiform activity. Mice either 
did not develop epileptiform (green traces), developed bouts of epileptic spikes (black traces) or showed 
continuous epileptiform activity (pink traces). Traces were filtered using a 0.005 Hz high pass filter (top traces) 
or a 0.5 Hz high pass filter (middle traces). The bottom traces represent magnifications of the parts of the middle 
traces depicted by the dashed squares (0.5 Hz high pass filter). The red lines above the black and pink traces 
indicate the occurrence of epileptiform activity. (B) Quantification of the proportion of mice showing either no 
epileptiform activity (green), bouts of epileptiform activity (black) or continuous epileptiform activity (pink) 
by the end of the recording (1 hour) for all groups (male, female, aged male and post-menopausal (PM) female 
α2+/G301R mice and their wild type littermates; (N = 7–9)). (C) Quantification of onset of epileptiform activity 
for male, female, aged male and post-menopausal (PM) female α2+/G301R mice and wild types (pooled due to 
low number of animals developing epileptiform activity) (N = 9–10). Error bars represent standard deviations, 
*p < 0.05, ***p < 0.001 (Kruskal-Wallis test and subsequent Dunn’s Multiple Comparison tests with Bonferroni 
correction; see Table 2). (D) Representative examples of 1 hour ECoG recordings (M1; 0.005 Hz high pass 
filter) in α2+/G301R mice (bottom 2 traces) and wild type littermates (top 2 traces) showing the progression of 
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The latter two combinations of channels were not significantly different (t(32) = 0.67, p = 0.507). This suggests, 
as expected, that whereas these correlations were generally quite high (~0.7 on average), epileptiform activity in 
either two different cortical areas of the same hemisphere or the same cortical area of different hemispheres was 
better correlated than the activity recorded from S1 and contralateral M1. Analyses of the timing of this peak in 
the cross-correlogram showed a somewhat different pattern. The epileptiform activity consistently occurs first 
in the primary motor cortex ipsilateral to the CSD induction site. The time difference between M1 and S1 on 
the ipsilateral hemisphere is very small and significantly shorter than the time difference between either of those 
channels and the contralateral M1 electrode (t(32) = −8.16, p ≤ 0.001 and t(32) = −11.09, p ≤ 0.001 respectively 
for M1 and S1; paired t-tests; Fig. 4G, Table 4) whereas there is no difference in timing between the ipsilateral 
electrodes and contralateral M1 (t(32) = 1.58, p = 0.125). These results indicate that the epileptiform activity 
occurs first in the ipsilateral hemisphere and likely spreads to the contralateral side from there.
Discussion
Migraine is a disabling disease which affects a large number of people at different levels. A key characteristic 
of FHM2 is the appearance of the aura phenomenon prior to the onset of the hemiplegic migraine, associated 
with CSD. Despite several lines of progress, the mechanisms underlying CSD remain poorly understood. In this 
study, we show that a mouse model for FHM2 harboring the G301R mutation shows an increased susceptibility 
to both CSD and generalized epileptiform activity in awake animals. These findings mimic symptoms described 
in FHM2 patients harboring the G301R mutation in the ATP1A2 gene10,11. Results from in vivo recordings in 
awake, head-restrained mice, show a substantial increase in CSD susceptibility in α2+/G301R mice that was similar 
to data obtained from FHM1 mouse models23. Migraine prevalence in humans1,3, CSD susceptibility in FHM1 
mice23,29, and prevalence of psychiatric and motor abnormalities in α2+/G301R mice12 have been shown to be higher 
in females and sensitive to blocking the female sex hormone cycle. We therefore assessed CSD susceptibility in 
adult and aged male and female mice. Whereas FHM1 models show an increased CSD susceptibility in females 
compared to males23, we do not find such an effect of gender. Interestingly, two of nine female α2+/G301R mice did 
show a higher CSD frequency than any of the other α2+/G301R mice, suggesting that a gender-based difference may 
be present in a limited period of the female menstrual cycle. This is in line with our finding that post-menopausal 
females show a significant decrease in CSD frequency comparable to aged and ovariectomized FHM1 models23 
and with the rescue of OCD-like behavior, depressed mood and hypo-locomotion in female α2+/G301R mice upon 
suppression of the hormonal cycle12. In contrast, aged males did not show a decreased CSD susceptibility, suggest-
ing that the partial rescue of the CSD phenotype in aged females is a consequence of menopause-like hormonal 
changes rather than age in general. Future pre-clinical studies should be carried out to investigate this phenome-
non further, for example by examining whether pharmacological or surgical ablation of sex hormones would also 
decrease susceptibility to CSD and epileptiform activity in fertile females, and whether this can be reversed by 
hormone replacement therapy. This could provide a basis for potential clinical trials looking into hormone-based 
treatment options for women suffering from migraine.
The occurrence of generalized epileptiform activity and coinciding tonic-clonic behavioral manifestations was 
observed in some wild types and all α2+/G301R mice, sometimes with lethal outcome. Interestingly, tonic-clonic 
seizures have also been described to co-occur with migraine attacks in a family with this mutation11. Additionally, 
the co-occurrence of epileptiform activity and CSD has been shown in rabbits14,30 and aneurismal subarachnoid 
hemorrhage patients31. High extracellular potassium concentrations have been known to result in epileptic dis-
charges since the 1950s27,28,32–35. In addition, both epilepsy and CSD have also been shown to increase extracel-
lular potassium concentrations32,36–38. Given that we are using a KCl solution, and that the resulting CSDs raise 
potassium levels even further, the occurrence of epileptiform discharges is not unexpected. The progression in 
the severity of the epileptiform activity suggests that extracellular potassium levels indeed increase over time. The 
dramatic increase in prevalence and severity of epileptiform activity in α2+/G301R mice can be attributed to the 
impaired functioning of astrocytes resulting in insufficient potassium clearance from the extracellular space9,39,40. 
In combination with a higher CSD frequency, this likely results in higher extracellular potassium levels in α2+/
G301R mice compared to wild types, resulting in more epileptiform activity. Another potential contributing factor 
concerns the dependency of the astrocytic glutamate clearance system on α2Na+/K+−ATPase4,12,41–43. Both astro-
cytic glutamate transporters, excitatory amino acid transporter 1 and 2 (EAAT1 and EAAT2) have been shown to 
be co-localized with α2Na+/K+-ATPase44. Glutamate clearance by these transporters depends on the Na+ gradi-
ent which relies on α2Na+/K+-ATPase45. Impairments in astrocytic glutamate uptake from the synaptic cleft have 
been shown in cultured hippocampal cells from α2G301R/G301R. embryonic mice12 and in another FHM2 model39. 
Increased extracellular glutamate concentration and EAAT2 deficiency have been shown to cause epilepsy46,47, 
suggesting a defective glutamate system may also contribute to the increased susceptibility in α2+/G301R mice. 
Susceptibility to epileptiform activity has also been shown in the S218L FHM1 mouse model; both spontaneous 
seizures and epileptic activity post CSD elicitation have been observed, yet such an occurrence has not been men-
tioned during KCl induced CSDs, likely due to the use of anesthesia23,29. Finally, epileptic seizures also occur dur-
ing or immediately after migraine aura in patients with this mutation11. The exclusivity of epilepsy occurrence in 
relation to aura suggests that it is likely that CSD related changes may underlie the epilepsy phenotype in patients 
as well. Cross-correlation analyses revealed that this epileptiform activity occurs first in M1 ipsilateral to the CSD 
epileptiform activity over time. Mice either did not develop epileptiform activity (green trace), developed bouts 
of epileptiform activity (black traces) or progressed to showing continuous epileptiform activity (pink trace). 
Arrows indicate onset of the epileptiform activity. Like in (A), The red lines above the black and pink traces 
indicate the occurrence of epileptiform activity.
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induction site. It then occurs in S1 and spreads to the contralateral side, suggesting that the epileptiform activity 
starts in ipsilateral M1and spreads from there. However, it cannot be excluded that the potassium diffuses into 
other brain areas, like the hippocampus, and that the epileptiform activity is initiated elsewhere. Yet, regardless of 
where it is initiated, our data clearly show the occurrence of epileptiform activity during CSD.
In summary, the neuro-electrophysiological in vivo evidence for increased susceptibility to CSD and epilepti-
form activity in the α2+/G301R mice suggests that this mouse model closely resembles human symptoms and can be 
utilized to study the neuropathology underlying migraine disorders. Furthermore, the simultaneous occurrence 
of epileptiform activity and CSD in awake α2+/G301R mice provides a unique opportunity to study the role of neu-
ronal activity in CSD. This could have important implications for the identification of novel therapeutic strategies.
Materials and Methods
Animals. All animal experiments were done in accordance with guidelines set, and approved, by IACUC at 
the Albert Einstein College of Medicine. Data were obtained from 2–8 and 14–20 month old male and female 
heterozygous α2+/G301R mice and their wild type littermates. The older group of female mice were well past the 
estimated age of 8 months at which murine menopause occurs48. Genotyping was done by Transnetyx (Cordova, 
TN, USA). The presence of the α2+/G301R mutation was confirmed by polymerase chain reaction (PCR) using 
AGCATTTCATCCAGCTGATCACA (forward) and CCCAGGATGAGGGACAGAAC (reverse) primers. The 
α2+/G301R mice12 were maintained on a C57BL/6 J background (Jackson laboratory, Bar Harbor, ME, USA). All 
animals were housed on a reversed light/dark cycle to prevent daytime experiments from interfering with their 
normal sleep cycle.
Surgical procedures. Mice were anesthetized using isoflurane (4% in 1.5 L/min O2) and kept under anes-
thesia on a lower dose (1.5–2% in 1.5 L/min O2). The head was shaved after which an incision was made to 
expose the skull. After thoroughly cleaning the exposed surface, a dental adhesive (OptiBond All-In-One; Kerr 
Corporation, Orange, CA, USA) was applied to the area. Five small burr holes (0.5 mm) were very carefully 
drilled to allow subdural implantation of three recording electrodes and a reference and ground electrode for 
electrocorticographical (ECoG) recordings. Recording electrodes were bilaterally placed over the primary motor 
cortex (M1; ±2 mm ML and +1 mm AP, relative to bregma) and unilaterally over the primary sensory cortex (S1; 
−2 mm ML (left) and −1 mm AP, relative to bregma). Reference and ground electrodes were placed over the 
superior colliculi (±1 mm ML and −1 mm AP relative to lambda). A larger craniotomy (~2 mm in diameter) was 
subsequently drilled over the occipital lobe to permit application of KCl. Dura was left intact during this proce-
dure; if the dura was damaged, the mouse was excluded. Three PFA coated tungsten wires (50 μm) with a small 
loop at the end to prevent penetration of the dura, were used as recording electrodes and silver chloride balltip 
electrodes were used as reference and ground electrodes. The electrodes were cautiously positioned in the holes 
and secured with Charisma (Heraeus Kulzer, Hanau, Germany), a light cured composite. When all electrodes 
were implanted, the connector was lowered onto the skull and secured with Charisma. A small well was made 
Compared groups N p-value H or t-value Statistical test
Differences in onset of epileptiform activity
Wild types (pooled) and α2+/G301R mice 46 <0.001 H(4) = 20.16 Independent samples
(Males, females, aged males and PM females) (10, 9, 9, 9, 9) Kruskal-Wallis test
Wild types 10 <0.05 t(17) = −19.94 Dunn’s Multiple Comparison Test
α2+/G301R males 9 (Bonferroni correction)
Wild types 10 ≤0.001 t(17) = −24.61 Dunn’s Multiple Comparison Test
α2+/G301R females 9 (Bonferroni correction)
Wild types 10 <0.05 t(17) = −20.17 Dunn’s Multiple Comparison Test
α2+/G301R aged males 9 (Bonferroni correction)
Wild types 10 0.519 t(17) = −11.94 Dunn’s Multiple Comparison Test
α2+/G301R PM females 9 (Bonferroni correction)
α2+/G301R males 9 1.000 t(16) = 4.67 Dunn’s Multiple Comparison Test
α2+/G301R females 9 (Bonferroni correction)
α2+/G301R males 9 1.000 t(16) = 0.22 Dunn’s Multiple Comparison Test
α2+/G301R aged males 9 (Bonferroni correction)
α2+/G301R males 9 1.000 t(16) = −8.00 Dunn’s Multiple Comparison Test
α2+/G301R PM females 9 (Bonferroni correction)
α2+/G301R females 9 1.000 t(16) = −4.44 Dunn’s Multiple Comparison Test
α2+/G301R aged males 9 (Bonferroni correction)
α2+/G301R females 9 0.451 t(16) = −12.67 Dunn’s Multiple Comparison Test
α2+/G301R PM females 9 (Bonferroni correction)
α2+/G301R aged males 9 1.000 t(16) = −8.22 Dunn’s Multiple Comparison Test
α2+/G301R PM females 9 (Bonferroni correction)
Table 2. Details of statistical tests performed on data shown in Figure 2C.
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around the craniotomy to hold the tip of a cotton-tipped applicator during experiments and non-toxic silicone 
(Kwik-Sil; World Precision Instruments, Sarasota, FL, USA) was subsequently used to close it off. Finally, two 
small 3D printed, low weight cylinders were secured to the pedestal using Charisma to allow for head-restraining 
using adjustable magnetic stands (Fig. 1B). After surgery the mouse was given an analgesic (flunixin, 2.5 mg/kg; 
Bimeda, Dublin, Ireland) and it was kept on a heating pad until fully awake. All animals were given a few days of 
recovery before experiments started.
Electrophysiological recordings. ECoG recordings were done in awake head-restrained mice for 1 hour. 
In order to be able to restrain mice in the setup, they were initially anesthetized shortly (~ 1 min). Recordings 
were initiated at least 20 minutes after inserting them in the setup to allow for the effects of the anesthesia to wear 
off completely. After this waiting period, the silicon covering the craniotomy was removed and after visual inspec-
tion of the exposed brain (intact dura, healthy looking brain) the experiment was initiated.
In order to assess susceptibility to cortical spreading depression, we performed experiments as described pre-
viously23. In short: we placed the tip of a small cotton-tipped applicator drenched in KCl solution (300 mM) gently 
on the dura of the occipital craniotomy to evoke CSDs, and recorded DC ECoG for 1 hour. The cotton-tipped 
applicator was kept moist throughout the experiment to allow for continuous KCl diffusion. After the hour, the 
exposed brain was thoroughly flushed with NaCl and the craniotomy was sealed off with silicone again. All mice 
that showed epileptiform activity during this experiment were anesthetized before being put back in their home 
cage to stop the pathological activity. Still 4 mice died shortly after a tonic-clonic seizure-like episode. If mice 
C
R² = 0.447
10
20
30
40
50
60
10 15 20 25 30
CSD frequency (CSDs / hr)
O
ns
et
 e
pi
le
pt
ifo
rm
 a
ct
iv
ity
 (m
in
)
***
B
N
or
m
al
iz
ed
 a
ve
ra
ge
 p
ow
er
 0
.5
-4
 H
z
R² = 0.299
0
20
40
60
80
10 15 20 25 30
CSD frequency (CSDs / hr)
***
D
Onset epileptiform activity (min)
N
or
m
al
iz
ed
 a
ve
ra
ge
 p
ow
er
 0
.5
-4
 H
z
R² = 0.302
0
20
40
60
80
10 20 30 40 50 60
***
A
10
 m
V
rm
s2
M
ag
ni
tu
de
 p
ow
er
 (V
   
 )
0
5
10
15
20 10 s
0 108642
Frequency (Hz)
Figure 3. Predictability of onset and severity of epileptiform activity by CSD frequency in α2+/G301R mice. (A) 
representative example of severe epileptiform activity (top) and the corresponding power spectrum (bottom). 
(B–D) Scatter plots showing linear relations between severity of epileptiform activity (as defined by the 
normalized power at the dominant frequency of the epileptiform activity) and CSD frequency (B), onset of 
epileptiform activity and CSD frequency (C) and severity and onset of epileptiform activity (D). ***p < 0.001 
(linear regression, see Table 3).
Compared groups N p-value t-value Statistical test
Relation CSD susceptibility and epilepsy
CSD frequency 36 ≤0.001 t(35) = 3.81 Linear regression
Power at dominant frequency epileptiform activity
CSD frequency 36 <0.001 t(35) = −5.24 Linear regression
Onset epileptiform activity
Onset epileptiform activity 36 ≤0.001 t(35) = −3.84 Linear regression
Power at dominant frequency epileptiform activity
Table 3. Details of statistical tests performed on data shown in Figure 3B, C and D.
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showed extremely epileptiform activity for prolonged periods of time (>20 min), the experiment was aborted 
prematurely to attempt to prevent death.
All ECoG data was recorded using a custom made amplifier (high pass filter: 0.001 Hz, Low pass filter, 1 kHz, 
gain: 11), digitized (BNC-2090A; National Instruments, Austin, TX, USA) and stored for further analysis. The 
extremely high input impedance minimized all potential temporal errors with regard to CSD waveform49.
Data analyses. Custom written algorithms (LabView; National Instruments, Austin, TX, USA) were used 
for all analyses. All ECoG data was down sampled to 300 Hz and filtered offline (0.005 Hz high pass for CSD data, 
Figure 4. Epileptiform activity is generalized and superimposed on CSDs. (A,B) Representative ECoG 
traces showing bouts of epileptiform activity (left) or late stage continuous epileptiform activity (right) that is 
generalized (apparent in both hemispheres) and superimposed on the CSD (note that the CSD does not spread 
to the contralateral hemisphere). All traces are from the same experiment but at 2 different time points; 30 min 
(left) or 55 min (right). Traces are shown using a 0.005 Hz (A) or 0.5 Hz (B) high pass filter and a 100 Hz low 
pass filter (both). The red lines above the traces indicate the occurrence of epileptiform activity. (C) Wavelets 
of the traces shown in (B) showing the change in frequency spectra over time. (D) Magnification of the part 
of the trace in (B) (right panel) depicted by the dotted square showing the timing of the epileptic spikes in all 
traces. (E) Average cross correlations between all combinations of the three ECoG channels (N = 33 mice). 
(F,G) Quantification of the maximum cross correlations (F) and timing of this maximum (G) for the three 
combinations of ECoG channels (M1 left vs S1 left, M1 left vs M1 right and S1 left vs M1 right). Error bars 
represent standard deviations, ***p < 0.001 (paired t-tests; see Table 4).
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0.5 Hz high pass for data involving epileptiform activity, 100 Hz low pass for all). A CSD was identified by the 
characteristic shifts in DC potential; an initial wave of depolarization followed by pronounced depression. The 
CSD frequency was determined by counting the number of CSDs per hour and propagating speed was assessed by 
dividing the distance between the two electrodes (2 mm) by the difference in onset of the wave of depolarization 
of the first CSD.
Epileptiform activity was identified by the synchronous occurrence of low frequency spikes in the ECoG sig-
nal and the coinciding tonic-clonic behavioral correlates. Activity in the contralateral hemisphere was checked in 
each mouse to assess whether the epileptiform activity was generalized. In each mouse that showed epileptiform 
activity, it would start in bouts. In a subset of mice, the bouts progressed into continuous epileptiform activity 
without interruptions. Onset of epileptiform activity was defined as the first moment at which clearly distin-
guishable spikes occurred in the ECoG. In order to objectively measure the severity of the epileptiform activity, 
we performed Fast Fourier transforms and calculated the average power at spike frequency (0.5–4 Hz) in the last 
10 minutes of a trace and normalized this to the average power at this frequency range in the first 10 minutes. To 
assess the relation in shape and timing of spikes between channels, cross correlation analyses were performed 
in α2+/G301R mice using a custom written LabView program. We used a Matlab node in LabView and applied the 
standard xcorr (coeff) function to assess the similarity between two vectors as a function of lag. Three out of the 
36 mice were excluded because one of the channels was not working properly.
Statistical analyses. Due to inequality of variances and because not all variables were normally distributed, 
statistical differences in CSD frequency, propagating speed and onset of epileptiform activity between the inde-
pendent groups of mice (young and aged, male and female α2+/G301R mice and their wild type littermates) were 
determined using non-parametric Mann Whitney U tests and Kruskal-Wallis tests followed by Dunn’s Multiple 
Comparison tests with Bonferroni correction in case of a significant result. Predictability of the degree of severity 
of the epileptiform activity and onset by CSD frequency was tested using linear regression analyses. Differences in 
maximum cross correlation and timing thereof between the different ECoG channels during epileptiform activ-
ity were assessed using paired t-tests. Two tailed testing was used in all cases in which a p-value was considered 
significant if below 0.05 (α).
All analyses were performed using SPSS 22 (IBM Corporation, New York, USA).
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